Yaron Werber
Stock Analyst at TD Cowen
(1.58)
# 3,432
Out of 5,005 analysts
38
Total ratings
38.46%
Success rate
-2.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yaron Werber
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IOBT IO Biotech | Downgrades: Hold | n/a | $0.48 | - | 2 | Sep 30, 2025 | |
| ONC BeOne Medicines AG | Reiterates: Buy | $334 | $343.87 | -2.87% | 1 | Apr 24, 2025 | |
| FBRX Forte Biosciences | Initiates: Buy | n/a | $15.49 | - | 1 | Jan 21, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | n/a | $34.94 | - | 1 | Dec 20, 2024 | |
| SEPN Septerna | Initiates: Buy | n/a | $20.68 | - | 1 | Nov 19, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $160 → $153 | $204.05 | -25.02% | 5 | Nov 15, 2024 | |
| BNTX BioNTech SE | Maintains: Hold | $132 → $122 | $105.49 | +15.65% | 5 | Nov 6, 2024 | |
| UPB Upstream Bio | Initiates: Buy | n/a | $18.63 | - | 1 | Nov 5, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $61 → $73 | $31.21 | +133.90% | 2 | Oct 21, 2024 | |
| EXEL Exelixis | Maintains: Buy | $27 → $34 | $40.09 | -15.19% | 2 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $59 | $69.15 | -14.68% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $67 | $32.06 | +108.98% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $25.56 | - | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.49 | - | 1 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.05 | - | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $26.41 | - | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $612 → $641 | $800.00 | -19.88% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.34 | - | 1 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $375 → $625 | $11.73 | +5,228.22% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $18.10 | - | 2 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $38 | $33.56 | +13.23% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $16.17 | - | 1 | Oct 26, 2021 |
IO Biotech
Sep 30, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.48
Upside: -
BeOne Medicines AG
Apr 24, 2025
Reiterates: Buy
Price Target: $334
Current: $343.87
Upside: -2.87%
Forte Biosciences
Jan 21, 2025
Initiates: Buy
Price Target: n/a
Current: $15.49
Upside: -
Dianthus Therapeutics
Dec 20, 2024
Initiates: Buy
Price Target: n/a
Current: $34.94
Upside: -
Septerna
Nov 19, 2024
Initiates: Buy
Price Target: n/a
Current: $20.68
Upside: -
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $160 → $153
Current: $204.05
Upside: -25.02%
BioNTech SE
Nov 6, 2024
Maintains: Hold
Price Target: $132 → $122
Current: $105.49
Upside: +15.65%
Upstream Bio
Nov 5, 2024
Initiates: Buy
Price Target: n/a
Current: $18.63
Upside: -
Ultragenyx Pharmaceutical
Oct 21, 2024
Maintains: Buy
Price Target: $61 → $73
Current: $31.21
Upside: +133.90%
Exelixis
Oct 21, 2024
Maintains: Buy
Price Target: $27 → $34
Current: $40.09
Upside: -15.19%
Jul 23, 2024
Maintains: Buy
Price Target: $54 → $59
Current: $69.15
Upside: -14.68%
Jul 15, 2024
Maintains: Buy
Price Target: $71 → $67
Current: $32.06
Upside: +108.98%
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $25.56
Upside: -
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $2.49
Upside: -
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $6.05
Upside: -
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $26.41
Upside: -
Dec 12, 2023
Maintains: Outperform
Price Target: $612 → $641
Current: $800.00
Upside: -19.88%
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.34
Upside: -
Feb 28, 2023
Maintains: Market Perform
Price Target: $375 → $625
Current: $11.73
Upside: +5,228.22%
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $18.10
Upside: -
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $33.56
Upside: +13.23%
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $16.17
Upside: -